

Drug Treatments

Reference Number: F4936 Date of Response: 21/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

I have a Freedom of information query. How many patients has your trust/health board treated in the past 6 months (for any disease) with the following drugs :

Aubagio (teriflunomide)	0 patients
Avonex (interferon beta-1a)	0 patients
Betaferon (interferon beta-1b)	* <5
Brabio (glatiramer acetate)	0 patients
Copaxone (glatiramer acetate) -	0 patients
Extavia (beta interferon-1b)	0 patients
Gilenya (fingolimod)	0 patients
Lemtrada (alemtuzumab)	0 patients
Kesimpta (ofatumumab)	12 patients
Mavenclad (cladribine)	0 patients
Mayzent (siponimod)	0 patients
Ocrevus (ocrelizumab)	0 patients
Plegridy (peginterferon beta-1a)	0 patients
Ponvory (ponesimod)	0 patients
Rebif (beta interferon-1a)	0 patients
Tecfidera (dimethyl fumarate)	6 patients
Tysabri (natalizumab)	0 patients
Tysabri (natalizumab) pre-filled syringes	0 patients
ONLY	
Vumerity (diroximel fumarate)	0 patients
Zeposia (ozanimod)	0 patients

* <5 low number suppressed to protect patient identity In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

It would also be very helpful if you could advise how many hospital patients seen in the past 6 months (as inpatients or outpatients) have a diagnosis for the following conditions:

- Multiple sclerosis (any type) 297 patients
- Relapsing remitting multiple sclerosis (RRMS) 381 patients
- Primary progressive multiple sclerosis (PPMS) 89 patients
- Secondary progressive multiple sclerosis (SPMS) 170 patients